Creating a new type of cell therapy to improve immune response control
Official title: Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
Funded at Indiana University Indianapolis · NIH-10894754 · Data updated 2026-11-12
This study is testing a new treatment that helps special immune cells called regulatory T cells work better in managing autoimmune diseases and hemophilia A, by giving them special tools to target a key protein, which could lead to longer-lasting and more effective relief from symptoms.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $239,768 |
| NIH project number | 5R21HL170146-02 |
| Project ID | NIH-10894754 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune diseases or hemophilia A who are experiencing issues with current therapies due to immune responses.
✕Less likely to help
Patients with conditions unrelated to immune response or those who do not have autoimmune diseases or hemophilia A may not benefit from this research.
What this research studies
This research focuses on developing a novel cellular therapy that enhances the ability of regulatory T cells (Tregs) to manage harmful immune responses in conditions like autoimmune diseases and hemophilia A. By engineering Tregs with specific receptors that target clotting factor VIII, the therapy aims to improve the effectiveness and longevity of these cells in the body. The approach utilizes advanced techniques such as CRISPR to create a more precise and durable immune response, potentially reducing the formation of anti-drug antibodies that can hinder treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with autoimmune diseases and hemophilia A, improving their quality of life and treatment outcomes.
How similar studies have gone: Previous research has shown promise in using engineered Tregs for immune modulation, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
Related research
Other NIH-funded projects on the same topics.
-
Adapting flow cytometry to detect childhood leukemias in Kenya using a single-test screen
A low-cost, blood-based flow cytometry screen in Kenya aims to detect and triage suspected leukemias in children and young adults.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.